




RealRate

PHARMACEUTICAL 2016

Sonnet Biotherapeutics Holdings Inc
Rank 186 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 27% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	3,819
Cost of Goods Sold	0
Intangible Assets	19,984
Liabilities, Current	16,181
Liabilities, Non-Current	1,099
Other Assets	1,761
Other Compr. Net Income	1,352
Other Expenses	46,657
Other Liabilities	3,168
Other Net Income	-2,780
Other Revenues	42,397
Property and Equipment	16,641
Research and Development	0
Selling, General and Administrative Expense	7,415

Output Variable	Value in 1000 USD
Assets	42,205
Liabilities	20,448
Expenses	54,072
Revenues	42,397
Stockholders Equity	21,757
Net Income	-14,456
Comprehensive Net Income	-13,780
BaseVar	81,627
ECR before LimitedLiability	107%
Economic Capital Ratio	236%